** Shares of Israel-based medical device maker IceCure Medical ICCM.O fall 17% to $1.22 in afternoon trading, their biggest one-day percentage fall in more than a year
** ICCM says it expects the FDA to make a decision on its ProSense system, used for the treatment of a type of breast cancer, after Q1 2025
** Co previously expected FDA's decision by Q1 2025
** Co's ProSense provides a minimally invasive treatment option to destroy tumors by freezing them
** ICCM has risen 19.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.